These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36468400)

  • 1. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
    Jones L; Jones AM
    Pharmacol Res Perspect; 2022 Dec; 10(6):e01029. PubMed ID: 36468400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
    Matharu K; Chana K; Ferro CJ; Jones AM
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.
    Salim H; Jones AM
    Br J Clin Pharmacol; 2022 Nov; 88(11):4812-4827. PubMed ID: 35585835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
    Deacon CF
    Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):48-56. PubMed ID: 23837679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent class analysis of patients' background factors affecting the risk of specific adverse drug reactions to dipeptidyl peptidase 4 inhibitors.
    Kaseda D; Hashiguchi M; Kizaki H; Hori S
    Int J Clin Pharmacol Ther; 2022 Aug; 60(8):346-357. PubMed ID: 35713161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
    Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
    Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
    Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
    Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
    Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
    J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.
    Sandhu D; Antolin AA; Cox AR; Jones AM
    Br J Clin Pharmacol; 2022 Feb; 88(2):742-752. PubMed ID: 34327724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
    Kridin K
    Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.
    Kridin K; Avni O; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
    Arch Dermatol Res; 2023 Jan; 315(1):33-39. PubMed ID: 35032198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
    Torrecillas-Baena B; Gálvez-Moreno MÁ; Quesada-Gómez JM; Dorado G; Casado-Díaz A
    Stem Cell Rev Rep; 2022 Jan; 18(1):56-76. PubMed ID: 34677817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight in the safety profile of antidiabetic agents glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in daily practice from the patient perspective.
    van Gorp AM; Rolfes L; Härmark L; van der Horst P; Hendriks J; Vorstenbosch S
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1588-1595. PubMed ID: 32854158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.